Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer

Tanja N Fehm, Manfred Welslau, Volkmar Müller, Diana Lüftner, Florian Schütz, Peter A Fasching, Wolfgang Janni, Christoph Thomssen, Isabell Witzel, Milena Beierlein, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P Lux, Bahriye Aktas, Maggie Banys-Paluchowski, Cornelia Kolberg-Liedtke, Andreas D HartkopfAchim Wöckel, Hans-Christian Kolberg, Nadia Harbeck, Elmar Stickeler


The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from the APHINITY study, and on how preoperative peritumoral application of local anesthetics can influence the prognosis. We also present solid data on dynamic Ki-67 from the ADAPT studies.

Original languageEnglish
JournalGeburtshilfe und Frauenheilkunde
Issue number03
Pages (from-to)289-298
Number of pages10
Publication statusPublished - 03.2023

Research Areas and Centers

  • Centers: University Cancer Center Schleswig-Holstein (UCCSH)
  • Research Area: Luebeck Integrated Oncology Network (LION)


Dive into the research topics of 'Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer'. Together they form a unique fingerprint.

Cite this